Adjuvant radiotherapy and chemotherapy (RT/chemo) is the standard of care for locally advanced rectal cancer patients. Recently, there has been increased usage of the preoperative RT/chemo sequence since it reduces the bulk of the tumor, enhances local- regional control and facilitates sphincter preservation. Although 9-30 percent of patients achieve a complete response, we cannot definitively differentiate them from those with residual pelvic disease. Through delineation of residual rectal cancer in the bowel wall or pelvic lymph nodes, we anticipate that FDG-PET will improve our selection of patients for sphincter preservation. Furthermore, 11-30 percent of rectal cancer patients receiving pre-op RT/chemo will have extrapelvic metastatic disease at exploration despite a normal preoperative CT scan and CXR. Clearly, patients with an excellent rectal cancer response to preoperative RT/chemo yet with extrapelvic disease should be spared radical abdominal surgery. We hypothesize that PET will alter clinical decision making in patients with locally advanced rectal cancer in terms of: optimal therapeutic strategy and also the ability of PET-FDG to monitor the response of tumors to RT/chemo. We propose a prospective comparison of FDG-PET and CT imaging in T3NO or T3N1 rectal cancer patients undergoing preoperative RT/chemo. Approximately 40 patients per year will be imaged before and after preoperative RT/chemo. PET parameters to be studied include traditional measures such as metabolic rate of tumor expressed as standardized uptake value (SUVavg and SUVmax) and PET derived tumor volume (Size) as well as two novel parameters that we have developed: visual response score (VRS) and the Larson-Ginsberg index (LGI), a measure of the change in total lesion glycolysis. This 3 year study on a sufficient number of patients (n=125) will compare FDG-PET and CT assessment of pathological response to preoperative RT/chemo. Another critical analysis will be the correlation of PET, CT and pathology with recurrence-free interval and disease-specific survival. In a subset of patients (n=30), we will initiate a pilot study to investigate the effect of RT/chemo on glucose transporter (GLUT) expression. Enhanced glycolysis is the basis for FDG uptake in malignant cells and changes in the profile of GLUT transporters may account for the cellular accumulation of FDG in tissues. An analysis of GLUT gene and protein expression will be performed on tumor specimens before and after RT/chemo by RT-PCR and immunohistochemistry, respectively. Alterations in the profile of GLUT expression in response to RT/chemo may provide insight on the effects of RT/chemo on glucose metabolism in rectal cancers. We hypothesize that FDG-PET will provide incremental information to physical exam and CT that will lead to improved individual patient management, specifically, by identifying patients suitable for sphincter preserving rectal cancer surgery as well as those not suitable for radical surgery.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA082534-02
Application #
6173803
Study Section
Diagnostic Radiology Study Section (RNM)
Program Officer
Wu, Roy S
Project Start
1999-07-01
Project End
2002-06-30
Budget Start
2000-07-01
Budget End
2001-06-30
Support Year
2
Fiscal Year
2000
Total Cost
$251,173
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Leibold, Tobias; Hui, Vanessa W; Shia, Jinru et al. (2014) p27 expression in post-treatment rectal cancer: a potential novel approach for predicting residual nodal disease. Am J Surg 208:228-34
O'Donoghue, Joseph A; Guillem, José G; Schöder, Heiko et al. (2013) Pilot study of PET imaging of 124I-iodoazomycin galactopyranoside (IAZGP), a putative hypoxia imaging agent, in patients with colorectal cancer and head and neck cancer. EJNMMI Res 3:42
Guillem, José G; Ruby, Jeannine A; Leibold, Tobias et al. (2013) Neither FDG-PET Nor CT can distinguish between a pathological complete response and an incomplete response after neoadjuvant chemoradiation in locally advanced rectal cancer: a prospective study. Ann Surg 258:289-95
Lee-Kong, Steven A; Ruby, Jeannine A; Chessin, David B et al. (2012) Hypoxia-related proteins in patients with rectal cancer undergoing neoadjuvant combined modality therapy. Dis Colon Rectum 55:990-5
Ruby, Jeannine A; Leibold, Tobias; Akhurst, Timothy J et al. (2012) FDG-PET assessment of rectal cancer response to neoadjuvant chemoradiotherapy is not associated with long-term prognosis: a prospective evaluation. Dis Colon Rectum 55:378-86
Balakrishnan, Kumudha; Stellrecht, Christine M; Genini, Davide et al. (2005) Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP. Blood 105:4455-62
Moore, Harvey G; Gittleman, Alicia E; Minsky, Bruce D et al. (2004) Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection. Dis Colon Rectum 47:279-86
Mazumdar, Madhu (2004) Group sequential design for comparative diagnostic accuracy studies: implications and guidelines for practitioners. Med Decis Making 24:525-33
Shia, Jinru; Guillem, Jose G; Moore, Harvey G et al. (2004) Patterns of morphologic alteration in residual rectal carcinoma following preoperative chemoradiation and their association with long-term outcome. Am J Surg Pathol 28:215-23
Guillem, Jose G; Moore, Harvey G; Akhurst, Timothy et al. (2004) Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer. J Am Coll Surg 199:1-7

Showing the most recent 10 out of 16 publications